We show that galacto‐conjugation of the BCL‐2 family inhibitor Navitoclax allows therapeutically relevant activity in subcutaneous tumour xenografts and orthotopic mouse models of chemotherapy‐induced senescence in the context of lung carcinoma. This evidence concerns the gene BCL2 and lung carcinoma.